| T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals V Naranbhai, A Nathan, C Kaseke, C Berrios, A Khatri, S Choi, MA Getz, ... Cell 185 (6), 1041-1051. e6, 2022 | 278 | 2022 |
| Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines V Naranbhai, WF Garcia-Beltran, CC Chang, C Berrios Mairena, ... The Journal of infectious diseases 225 (7), 1141-1150, 2022 | 134 | 2022 |
| Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses A Nathan, EJ Rossin, C Kaseke, RJ Park, A Khatri, D Koundakjian, ... Cell 184 (17), 4401-4413. e10, 2021 | 67 | 2021 |
| HLA class-I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV C Kaseke, RJ Park, NK Singh, D Koundakjian, A Bashirova, WFG Beltran, ... Cell Reports 36 (2), 2021 | 21 | 2021 |
| Viral and host mediators of non-suppressible HIV-1 viremia A Mohammadi, B Etemad, X Zhang, Y Li, GJ Bedwell, R Sharaf, A Kittilson, ... Nature Medicine 29 (12), 3212-3223, 2023 | 18 | 2023 |
| The emerging role for CTL epitope specificity in HIV cure efforts C Kaseke, R Tano-Menka, F Senjobe, GD Gaiha The Journal of Infectious Diseases 223 (Supplement_1), S32-S37, 2021 | 16 | 2021 |
| T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals V Naranbhai, A Nathan, C Kaseke, C Berrios, A Khatri, S Choi, MA Getz, ... MedRxiv, 0 | 12 | |
| A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta B Carter, P Huang, G Liu, Y Liang, PJC Lin, BH Peng, LGA McKay, ... Frontiers in immunology 14, 1135815, 2023 | 9 | 2023 |
| Preferential expansion upon boosting of cross-reactive “pre-existing” switched memory B cells that recognize the SARS-CoV-2 Omicron variant Spike protein CA Perugino, H Liu, J Feldman, BM Hauser, C Jacob-Dolan, A Nathan, ... medRxiv, 2021.12. 30.21268554, 2022 | 9 | 2022 |
| T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals. medRxiv [Epub ahead of print] V Naranbhai, A Nathan, C Kaseke, C Berrios, A Khatri, S Choi, MA Getz, ... DOI 10 (2022.01), 04.21268586, 2022 | 5 | 2022 |
| Preliminary immunogenicity of a pan-COVID-19 T cell vaccine in HLA-A* 02: 01 mice B Carter, J Chen, C Kaseke, A Dimitrakakis, GD Gaiha, Q Xu, DK Gifford bioRxiv, 2021.05. 02.442052, 2021 | 1 | 2021 |
| Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules R Tano-Menka, NK Singh, I Muzhingi, X Li, MV Mandanas, C Kaseke, ... Structure, 2024 | | 2024 |
| A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta PJG Bettencourt, Y Yoshioka, CTK Tseng, DK Gifford, B Carter, P Huang, ... | | 2023 |
| Residues in HLA class I that Account for Variation of the HIV Host Response Distinctly Modulate Interactions with TCR and KIRs R Tano-Menka, N Singh, I Muzhingi, X Li, M Mandanas, C Kaseke, ... | | 2022 |
| Applying insights from HIV to guide the development of a T-cell vaccine for SARS-CoV-2. A Nathan, G Gaiha, E Rossin, C Kaseke, RT Menka, B Walker Journal of the International AIDS Society 24 (S1), 23-25, 2021 | | 2021 |
| Viral and Host Mediators of Non-Suppressible HIV-1 Viremia AK Sharaf, M Melberg, C Wong, J Fajnzylber, P Daniel, AR Worrall, ... | | |
| Immunogenicity of mRNA-1273, BNT162b2 and Ad26. COV2. S COVID-19 vaccines C Lam, C Kaseke, R Tano-Menka, M Pavlovic, MD Poznansky, GD Gaiha, ... | | |
Gaurav D GaihaRagon Institute, MGH, Harvard Medical School在 mgh.harvard.edu 的电子邮件经过验证
